Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN

Peregrine Capital Management LLC raised its position in shares of Organon & Co. (NYSE:OGN) by 99.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 536,728 shares of the company’s stock after buying an additional 267,016 shares during the quarter. Peregrine Capital Management LLC owned about 0.21% of Organon & Co. worth $5,196,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ransom Advisory Ltd purchased a new position in Organon & Co. during the first quarter valued at $32,000. Hanson & Doremus Investment Management purchased a new position in Organon & Co. during the second quarter valued at $26,000. Brooklyn Investment Group lifted its position in Organon & Co. by 1,012.3% during the first quarter. Brooklyn Investment Group now owns 3,070 shares of the company’s stock valued at $46,000 after buying an additional 2,794 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Organon & Co. during the first quarter valued at $51,000. Finally, PARK CIRCLE Co lifted its position in Organon & Co. by 640.7% during the first quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock valued at $60,000 after buying an additional 3,460 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on OGN. Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. Piper Sandler downgraded Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Organon & Co. presently has a consensus rating of “Hold” and a consensus price target of $13.00.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $6.65 on Wednesday. Organon & Co. has a 1-year low of $6.39 and a 1-year high of $19.05. The business has a fifty day moving average price of $9.82 and a 200-day moving average price of $9.81. The company has a market capitalization of $1.73 billion, a PE ratio of 2.47, a PEG ratio of 0.64 and a beta of 0.63. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.55 billion. During the same period last year, the company earned $1.12 EPS. Organon & Co.’s revenue for the quarter was down .8% on a year-over-year basis. Organon & Co. has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were issued a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 1.2%. The ex-dividend date was Friday, August 15th. Organon & Co.’s dividend payout ratio (DPR) is presently 2.97%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.